Search

Search Constraints

You searched for: Subject interstitial fibrosis

Search Results

31. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). Issue 1 (30th December 2021)

32. Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis. Issue 1 (26th March 2021)

33. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. Issue 1 (25th March 2019)

34. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. Issue 1 (15th January 2021)

35. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. Issue 1 (15th January 2021)

36. Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. Issue 1 (15th January 2021)

37. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. Issue 1 (5th July 2020)

38. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. Issue 1 (5th July 2020)

39. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. Issue 1 (5th July 2020)

40. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. Issue 1 (5th July 2020)